scholarly journals The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors

2013 ◽  
Vol 14 (8) ◽  
pp. 16348-16364 ◽  
Author(s):  
Sylwester Glowacki ◽  
Ewelina Synowiec ◽  
Janusz Blasiak
Keyword(s):  
Dna Damage ◽  
Mitochondrial Dna ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Dna Damage And Repair ◽  
Mitochondrial Dna Damage

A REVIEW ON THE ROLE OF TYROSINE KINASE INHIBITORS AVAILABLE FOR THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA

2020 ◽  
Vol 7 (2) ◽  
pp. 205-211
Author(s):  
Kaynat Fatima ◽  
Syed Tasleem Raza ◽  
Ale Eba ◽  
Sanchita Srivastava ◽  
Farzana Mahdi
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Protein Kinases ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

The function of protein kinases is to transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are linked to the initiation and development of human cancer. The recent development of small molecule kinase inhibitors for the treatment of different types of cancer in clinical therapy has proven successful. Significantly, after the G-protein-coupled receptors, protein kinases are the second most active category of drug targets. Imatinib mesylate was the first tyrosine kinase inhibitor (TKI), approved for chronic myeloid leukemia (CML) treatment. Imatinib induces appropriate responses in ~60% of patients; with ~20% discontinuing therapy due to sensitivity, and ~20% developing drug resistance. The introduction of newer TKIs such as, nilotinib, dasatinib, bosutinib, and ponatinib has provided patients with multiple options. Such agents are more active, have specific profiles of side effects and are more likely to reach the necessary milestones. First-line treatment decisions must be focused on CML risk, patient preferences and comorbidities. Given the excellent result, half of the patients eventually fail to seek first-line treatment (due to discomfort or resistance), with many of them needing a third or even further therapy lines. In the present review, we will address the role of tyrosine kinase inhibitors in therapy for chronic myeloid leukemia.

scholarly journals Potential role of tyrosine kinase inhibitors during primary HIV-1 infection

2017 ◽  
Vol 15 (5) ◽  
pp. 421-423 ◽  
Author(s):  
Juan Ambrosioni ◽  
Mayte Coiras ◽  
José Alcamí ◽  
José M. Miró
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Potential Role ◽  
Kinase Inhibitors ◽  
Hiv 1

scholarly journals Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review

2006 ◽  
Vol 17 (8) ◽  
pp. 1185-1196 ◽  
Author(s):  
P. Schöffski ◽  
H. Dumez ◽  
P. Clement ◽  
A. Hoeben ◽  
H. Prenen ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Cell Cancer ◽  
Advanced Renal Cell Cancer

The role of mitochondrial DNA damage in the citotoxicity of reactive oxygen species

2011 ◽  
Vol 43 (1) ◽  
pp. 25-29 ◽  
Author(s):  
R. A. P. Costa ◽  
C. D. Romagna ◽  
J. L. Pereira ◽  
N. C. Souza-Pinto
Keyword(s):  
Reactive Oxygen Species ◽  
Dna Damage ◽  
Mitochondrial Dna ◽  
Reactive Oxygen ◽  
Oxygen Species ◽  
Mitochondrial Dna Damage

scholarly journals The role of tyrosine kinase inhibitors in tuberous sclerosis

2009 ◽  
Vol 147 (1) ◽  
pp. 152-153 ◽  
Author(s):  
Başak Koluman ◽  
Zeynep Arzu Yegin ◽  
Münci Yağcı
Keyword(s):  
Tyrosine Kinase ◽  
Tuberous Sclerosis ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document